Haian Fu, PhD
Professor and Chair
Emory University School of Medicine
Winship Partner in Research Endowed Chair
Winship Cancer Institute of Emory University
Office: 5111 Rollins Research Center
Phone: 404-727-0368; Lab Number: 404-727-1335
Additional Contact Information
Emory University School of Medicine
Department of Pharmacology
1510 Clifton Road, Rollins Research Center Room 5111
Atlanta, Georgia 30322-3090
- PhD, University of Wisconsin-Madison, 1989
- Postdoctoral Fellow, Harvard Medical School, 1989-1991
- Instructor, Harvard Medical School, 1991-1994
- Emory University, 1994
Cancer Biology & Chemical Biology
Cancer Biology & Chemical Biology: Studying cell survival signaling for therapeutic agent discovery and translational research.
Our research seeks to understand signal transduction pathways that control cell survival and death in normal and cancer cells. Based on newly discovered oncogenic signaling mechanisms, we employ a chemical biology approach to gain further insights into the molecular basis of cancer and to develop small molecule modulators for drug discovery and translational research.
• Survival signaling pathway studies. We are interested in identifying mechanisms that couple survival signaling to the apoptotic machinery. One such mechanism is mediated by the 14-3-3 protein family. 14-3-3 suppresses apoptosis in part through binding to death-promoting proteins such as ASK1 and Bad. We are taking steps to dissect the roles of 14-3-3 in mitogenic and apoptotic signaling pathways. Because of its role in mitogenic signaling and tumorigenesis, 14-3-3 is used as a probe for identifying novel regulatory proteins that promote or suppress tumorigenesis.
• Small molecule modulator identification for probe and drug discovery. One hallmark of cancer is the upregulation of cell survival. We are designing mechanism-based bioassays for high throughput and high content screening (HTS/HCS) of compounds for signaling modulators, such as 14-3-3 and ASK1 inhibitors. Such compounds will be developed as probes for mechanistic studies and for drug discovery.
• Translational research. To translate our basic understanding of survival signaling into clinical settings, we collaborate with physician scientists to develop novel therapeutic strategies for the prevention and treatment of cancer. In addition, we collaborate with chemists to develop new anticancer agents that can modulate survival pathways with the hope of moving more effective therapeutics into the clinic.
Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, Webber P, McMillan E, Rusnak L, Pham C, Chen X, Mo X, Revennaugh B, Zhou W, Marcus AI, Harati S, Chen X, Johns MA, White MA, Moreno C, Cooper LAD, Du Y, Khuri FR, Fu H (2017). The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies. Nature Communications 8, 14356 doi: 10.1038/ncomms14356 [http://www.nature.com/articles/ncomms14356]
Zhentao Zhang, Obiamaka Obianyo, Elfriede Dall, Yuhong Du, Haian Fu, Xia Liu, Seong Kang, Mingke Song, Shan Yu, Chiara Cabrele, Mario Schubert, Xiaoguang Li, Jian-Zhi Wang, Hans Brandstetter, and Keqiang Ye (2017) Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease, Nature Communications (in press)
Horton JR, Liu X, Gale M, Wu L, Shanks JR, Zhang X, Webber PJ, Bell JS, Kales SC, Mott BT, Rai G, Jansen DJ, Henderson MJ, Urban DJ, Hall MD, Simeonov A, Maloney DJ, Johns MA, Fu H*, Jadhav A*, Vertino PM, Yan Q, Cheng X. (2016) Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds. Cell Chem Biol. 21;23(7):769-81. doi: 10.1016/j.chembiol.2016.06.006. PMID: 27427228(*co-senior author)
Gu L, Zhang H, Liu T, Zhou S, Du Y, Xiong J, Yi S, Qu CK, Fu H, Zhou M. (2016) Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell. 2016 Oct 10;30(4):623-636. doi: 10.1016/j.ccell.2016.08.015. PMID: 27666947
- View publications on PubMed